Key result
Enalapril lowers blood pressure and albuminuria in diabetic hypertensive rats.
Answers are grounded in this paper and cite their sources.
To evaluate whether hypertension is a cause or just an association with diabetic renal disease, diabetes was induced in both normotensive Wistar-Kyoto and spontaneously hypertensive rats (WKY and SHR). Animals were assessed monthly for 8 months before sacrifice. When compared to normotensive diabetic rats (WKY-STZ), hypertensive diabetic rats (SHR-STZ) had an earlier and more rapid rise in urinary albumin excretion. In addition, SHR-STZ had increased glomerular basement membrane thickness when compared to WKY-STZ or SHR. In a separate experiment, Enalapril therapy (35 mg/L) was administered in drinking water to WKY-STZ and SHR-STZ. Enalapril significantly reduced blood pressure in both animal groups, and this was associated with a decrease in urinary albumin excretion. The SHR-STZ model has accelerated nephropathy as determined by both functional and structural parameters. Angiotensin-converting enzyme inhibition is associated with a reduction in albuminuria in both hypertensive and normotensive models of diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Cooper et al. (1988) studied Diabetic nephropathy and genetic hypertension. Genetic hypertension (SHR-STZ) and Enalapril vs. Normotensive diabetic rats (WKY-STZ) or untreated diabetic rats was evaluated on Urinary albumin excretion and glomerular basement membrane thickness. Genetic hypertension in diabetic rats accelerated urinary albumin excretion and glomerular basement membrane thickening over 8 months, while enalapril reduced blood pressure and albuminuria.
Synapse has enriched 10 related papers. Consider them for comparative context: